-
It is not simple, five interpretations of the cause of elevated leukocytes in a patient with thalassaemia major
Time of Update: 2022-04-21
So what caused the increase in peripheral blood WBC of this patient?Reviewing the life course of WBC: pluripotent hematopoietic stem cells are directed to differentiate into myeloid progenitor cells under the action of colony-stimulating factors, and then develop into promyeloid, mesoderm, metamyeloid, rod-shaped nucleus and lobulated nucleus after several mitotic divisions.
-
Blood: Obinutuzumab + ibrutinib + venetoclax for first-line treatment of high-risk chronic lymphocytic leukemia
Time of Update: 2022-04-21
Finally, patients who did not achieve complete remission (CR) after consolidation therapy and had several consecutive undetectable minimal residual disease (uMRD) received an additional 24 cycles of ibrutinib monotherapy .
-
Leukemia: Comparison of survival outcomes in autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL
Time of Update: 2022-04-15
A research team retrospectively evaluated survival outcomes in 760 adult patients with R/R PTCL-NOS or AITL who underwent their first HCT .
A team of researchers retrospectively assessed survival outcomes in 760 adult patients with R/R PTCL-NOS or AITL who underwent their first HCT .
-
JAMA Intern Med: Oral Daprodustat regimen for anemia in chronic kidney disease
Time of Update: 2022-04-15
Changes in HD level and iron injection amount between groupsThe study concluded that Daprodustat is an effective oral erythropoiesis-stimulating treatment regimen for patients with anemia in chronic kidney disease as effective as dabepox alfa .
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients A Randomized Clinical Trial JAMA
-
Public health expert Lu Hongzhou: Omi Kron is not the "final whistle" of the new crown epidemic, nor is it a big flu
Time of Update: 2022-04-15
In his view, several previous domestic epidemics caused by "article-to-human transmission" still need further research; because the antibodies in infected people are unsustainable, some people (about 8% of the population) do not produce neutralizing antibodies, and the "herd immunity" strategy Not advisable; the virus is changing, and vaccine development is constantly improving .
-
CAR-T is expected to be a highly effective therapy for relapsed and refractory indolent non-Hodgkin lymphoma
Time of Update: 2022-03-09
Of all 148 treated patients (updated analysis population), the majority had received at least three prior lines of therapy, and high-risk disease features were common; MZL patients were ≥65 years of age and had stage IV disease at a higher rate than FL patients, from diagnosis The median time to leukapheresis was 5.
-
A new choice for the treatment of thalassemia!
Time of Update: 2022-03-09
▎WuXi AppTec content team editor Recently, an erythrocyte maturation agent, rotercept for injection (trade name: Librozer®), has been approved by the National Medical Products Administration (NMPA) of China for the treatment of needs Adult patients with beta-thalassemia who receive regular RBC transfusions and RBC transfusions ≤15 units/24 weeks .
-
Transformation and prognosis of nodular lymphocyte-predominant Hodgkin lymphoma: a Finnish national population-based study
Time of Update: 2022-03-09
Ilja Kalashnikov et al conducted a Finnish national population-based study to assess the risk and relative survival of transformation to large B-cell lymphoma in Finnish patients diagnosed with NLPHL from 1995 to 2018, comparing disease transformation with and without disease transformation mortality of patients .
-
Annual Inventory Summary of Peripheral T-Cell Lymphoma Progress in 2021
Time of Update: 2022-03-09
Dehui Zou: Analysis of Clinical Characteristics and Efficacy of Peripheral T-cell LymphomaProfessor Zhang Liling at the 6th Anti-Leukemia and Lymphoma International Summit Forum with the title of "New Progress and Practice Sharing of Targeted Therapy for Peripheral T-cell Lymphoma", In-depth discussions were conducted in three aspects: "current status of peripheral T-cell lymphoma (PTCL) treatment", "optimization of initial treatment regimens", and "exploration of relapsed and refractory regimens" .
-
Professor Li Xiaoling, a big coffee explores "Ao": the initial application of ortuzumab shows good safety, and medical insurance helps more Chinese FL patients to benefit
Time of Update: 2022-03-09
The global phase III GALLIUM study in treatment-naïve FL patients showed that compared with rituximab plus chemotherapy, octuzumab combined with chemotherapy reduced the risk of recurrence and death by 34% in patients with early-stage disease The risk of progression decreased by 46% .
-
Big Coffee Review-Professor Jiang Erlie: The first-in-class drug Avonib was approved for marketing in China, and its key research AG120-C-001 and China bridging research CS3010-101 were analyzed
Time of Update: 2022-03-09
Conclusions from the Study of Grade ≥3 Treatment-Related Adverse Events In patients with IDH1-mutant R/R AML, 500 mg of ivonib daily induces durable remission, and patients with transfusion dependence at baseline were in all remission categories Transfusion independence was observed in all patients, and febrile neutropenia and infection frequency were reduced in remission patients, and were well tolerated, with 23% of CR/CRh patients achieving molecular remission .
-
Molecular mechanism of Cell Stem Cell E3 ubiquitin ligase TRAF6 regulating the development of myeloid malignancies
Time of Update: 2022-03-09
e. hematopoietic stem progenitor cells) can proliferate clonally in vitro and in vivo, and proved that TRAF only works in CHIP-related gene mutations (such as TET2) can promote the malignant transformation of pre-leukemia hematopoietic stem progenitor cells .
-
[Nature] The latest paper by the father of CAR-T: CAR-T cell therapy has cured cancer for ten years, and there has been no recurrence so far!
Time of Update: 2022-03-09
Tens of thousands of patients are currently being treated with CAR-T cell therapy, which has been approved by health authorities around the world, including the FDA, for certain blood cancers, June said .
-
Long-term follow-up results of phase II study of cladribine combined with rituximab in the treatment of variant hairy cell leukemia announced
Time of Update: 2022-03-09
Among the 17 patients who achieved blood MRD negativity after CDAR treatment, the median survival was 70.
There are currently 7 patients with negative blood MRD for a duration of 27-139 months (median 59.
-
Delivering good news to patients with malignant blood cancer, innovative stem cell transplant products are one step closer to approval
Time of Update: 2022-03-09
▎WuXi AppTec Content Team Editor On February 9, 2022, Gamida Cell announced that it has initiated rolling submission of the Biologics License Application (BLA) for the stem cell/bone marrow transplant product omidubicel to the U.
-
Annual Review Professor Jing Hongmei: Targeted drugs and CAR-T therapy bring new hope for the treatment of mantle cell lymphoma
Time of Update: 2022-03-09
At the beginning of the new year in 2022, Yimaitong specially invited Professor Jing Hongmei from Peking University Third Hospital to review the progress of MCL treatment in 2021 and discuss the future research direction of MCL .
-
$2 billion worth!
Time of Update: 2022-03-09
February 8, 2022 / eMedClub News / -- Biotechnology company CSL Behring recently announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating the AAV5-based gene therapy drug etranacogene dezaparvovec (EtranaDez) Subjects experienced stable and durable increases in mean factor IX (FIX) activity and hemostatic protection at 18 months .
-
Annual Inventory 2021 Summary of Progress in Diffuse Large B-Cell Lymphoma
Time of Update: 2022-03-09
2021 CSCO Expert Interview｜Professor Cai Qingqing talks about the treatment of diffuse large B-cell lymphoma Progress 3.
Zhao Donglu: Application Progress of Novel Antibodies in Diffuse Large B-Cell Lymphoma | 2021 Leukemia and Lymphoma Summit Forum 6.
-
Efficacy and safety of itacitinib versus placebo combined with corticosteroids in the treatment of acute graft-versus-host disease (GRAVITAS-301)
Time of Update: 2022-03-09
>>>Study Results Research Process and Baseline The GRAVITAS-301 trial enrolled 439 eligible patients between July 19, 2017, and October 3, 2019, who were randomly assigned to itacitinib (N=219) or placebo group (N=220) (see Figure 1 for details) .
-
Thalassaemia treatment, remove old "cloth" new!
Time of Update: 2022-03-09
The primary endpoint of the study showed that between weeks 13 and 24, the proportion of patients in the rotercept group with a ≥33% reduction in transfusion burden (and at least 2 units of red blood cells) was nearly 5 times higher than in the placebo group (21.
